SANDOZ ALISKIREN TABLET

Valsts: Kanāda

Valoda: angļu

Klimata pārmaiņas: Health Canada

Aktīvā sastāvdaļa:

ALISKIREN (ALISKIREN FUMARATE)

Pieejams no:

SANDOZ CANADA INCORPORATED

ATĶ kods:

C09XA02

SNN (starptautisko nepatentēto nosaukumu):

ALISKIREN

Deva:

150MG

Zāļu forma:

TABLET

Kompozīcija:

ALISKIREN (ALISKIREN FUMARATE) 150MG

Ievadīšanas:

ORAL

Vienības iepakojumā:

28

Receptes veids:

Prescription

Ārstniecības joma:

RENIN INHIBITORS

Produktu pārskats:

Active ingredient group (AIG) number: 0152352001; AHFS:

Autorizācija statuss:

CANCELLED PRE MARKET

Autorizācija datums:

2017-12-06

Produkta apraksts

_ _
_Sandoz Aliskiren Page 1 of 28_
PRODUCT MONOGRAPH
PR
SANDOZ ALISKIREN
aliskiren (as aliskiren fumarate)
Tablets, 150 and 300 mg
Renin inhibitor
Sandoz Canada Inc.
145 Jules-Léger
Boucherville (QC)
J4B 7K8
Date of Revision: August 31, 2016
Submission Control No: 197205
_ _
_Sandoz Aliskiren Page 2 of 28_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION..........................................................
3
SUMMARY PRODUCT INFORMATION
.................................................................... 3
INDICATIONS AND CLINICAL USE
...........................................................................
3
CONTRAINDICATIONS
.................................................................................................
3
WARNINGS AND PRECAUTIONS
...............................................................................
4
ADVERSE REACTIONS
.................................................................................................
8
DRUG INTERACTIONS
................................................................................................
12
DOSAGE AND ADMINISTRATION
...........................................................................
15
OVERDOSAGE
...............................................................................................................
16
ACTION AND CLINICAL PHARMACOLOGY
........................................................ 16
STORAGE AND STABILITY
.......................................................................................
19
DOSAGE FORMS, COMPOSITION AND PACKAGING
........................................ 19
PART II: SCIENTIFIC INFORMATION
...............................................................................
20
PHARMACEUTICAL INFORMATION
.....................................................................
20
CLINICAL TRIALS
.......................................................................................................
21
DETAILED PHARMACOLOGY
........................................................................